Pre-existing immunity to adeno-associated virus (AAV)2 limits transgene expression following intracerebral AAV2-based gene delivery in a 6-hydroxydopamine model of Parkinson's disease.

Shorena Janelidze, Ulrika Nordström, Sebastian Kügler, Patrik Brundin

Research output: Contribution to journalArticlepeer-review

5 Citations (SciVal)
30 Downloads (Pure)

Abstract

Adeno-associated virus (AAV) vectors are used to deliver potentially therapeutic genes in clinical trials in Parkinson's disease (PD). Pre-existing immunity to AAV and a local neuroinflammatory response might negatively affect the efficacy of such AAV-mediated gene delivery.
Original languageEnglish
Pages (from-to)300-308
JournalJournal of Gene Medicine
Volume16
Issue number9-10
DOIs
Publication statusPublished - 2014

Bibliographical note

The information about affiliations in this record was updated in December 2015.
The record was previously connected to the following departments: Clinical Memory Research Unit (013242610), Neuronal Survival (013212041)

Subject classification (UKÄ)

  • Neurosciences
  • Neurology

Fingerprint

Dive into the research topics of 'Pre-existing immunity to adeno-associated virus (AAV)2 limits transgene expression following intracerebral AAV2-based gene delivery in a 6-hydroxydopamine model of Parkinson's disease.'. Together they form a unique fingerprint.

Cite this